Head and Neck Squamous Cell CarcinomaNCT07766226
Online Sharing for Head & Neck Cancer Support
A study testing Social Sharing-Based Mobile Application in people with Head and Neck Squamous Cell Carcinoma, run by West China Hospital at 1 site in China.
Trial summary
Head and neck cancer patients often experience significant anxiety and depression during radiation therapy, which can affect their quality of life and treatment adherence. However, traditional psychological support is limited by resource constraints and accessibility. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Head and Neck Squamous Cell Carcinoma
- What is being tested?
- Social Sharing-Based Mobile Application
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 120 participants
- Where
- 1 siteChina
- Study dates
- 28 Aug 2026to 1 Feb 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18 - 75 years, male or female
- Life expectancy ≥ 6 months
- Histopathologically confirmed head and neck squamous cell carcinoma (including nasopharyngeal carcinoma) without distant metastasis
- Planned to receive curative radiotherapy or postoperative adjuvant radiotherapy
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- Adequate cognitive and reading ability to complete questionnaires
Show all 9Show fewer
- Ability to use a smartphone or tablet device
- Fluent in Chinese (reading and speaking)
- Willing and able to provide signed informed consent
Who cannot join
- Other malignancies (except treated basal cell skin cancer or cervical CIS)
- Prior head and neck radiotherapy
- History of psychiatric disorder or psychotropic medication use
- Absolute contraindication to head and neck radiotherapy
- Uncontrolled systemic disease (poorly controlled DM, NYHA III-IV HF, interstitial lung disease)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041
Xingchen Peng, 18980606753, pxx2014@163.com
About this study
Official title: A Prospective Randomized Controlled Trial of Network Platform Sharing Intervention for Psychological Outcomes in Patients With Head and Neck Squamous Cell Carcinoma Undergoing Radiotherapy
Head and neck cancer patients often experience significant anxiety and depression during radiation therapy, which can affect their quality of life and treatment adherence. However, traditional psychological support is limited by resource constraints and accessibility. This study aims to evaluate whether a mobile application based on social sharing and peer interaction can improve psychological distress in patients with head and neck squamous cell carcinoma (HNSCC) undergoing radiotherapy.
This is a prospective, randomized, parallel-group, open-label trial. A total of 120 participants will be randomly assigned in a 1:1 ratio to either the immediate intervention group or a waitlist control group. Participants in the intervention group will use a dedicated app featuring daily sharing, peer interaction (anonymous comments, likes, private messaging), psychoeducational resources, and reminders. The control group will receive a printed psychoeducational booklet during the initial phase and will gain access to the app after the primary endpoint assessment.
Read more
The primary outcome is the change in anxiety score (HADS-A) from baseline to completion of radiotherapy. Secondary outcomes include depression scores (HADS-D), radiotherapy interruption rate, app engagement, and severe psychological distress prevalence. Exploratory outcomes include quality of life (EORTC QLQ-C30, H\&N35), readmission rate, adverse event severity (CTCAE v5.0), and biological markers (e.g., cortisol, IL-6, CRP).
The study is expected to run from April 2026 to August 2027. Findings may inform scalable digital psychosocial interventions for cancer patients.
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Being tested
- Social Sharing-Based Mobile Application, Usual Care with Psycho-educational Manual
- Medical subject headings
- Squamous Cell Carcinoma of Head and Neck
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Social Sharing-Based Mobile ApplicationOther
Mobile app with five modules: daily sharing, anonymous peer interaction, psychoeducational resources, task reminders, and professional support. Participants post ≥2 shares and interact ≥3 times weekly for 8 weeks. Content moderated by research assistants.
Usual Care with Psycho-educational ManualOther
Participants receive standard radiotherapy care and a printed psychological adjustment manual, without access to the social sharing APP during the initial intervention phase.
| Study group | Role | What they receive |
|---|---|---|
| Online Sharing Group | Experimental | Participants receive immediate access to the social sharing-based mobile app intervention. The active intervention phase begins at radiotherapy initiation and lasts for 8 weeks, through 4 weeks post-radiotherapy, during which participants are encouraged to post at least 2 shares and complete at least 3 interactions per week. App access remains open thereafter for voluntary use through 12 weeks post-radiotherapy. Receives: Other: Social Sharing-Based Mobile Application |
| Control Group | Other | Participants receive a printed psychoeducational booklet during the initial phase and will gain access to the same app intervention after the primary endpoint assessment (radiotherapy completion). Receives: Other: Usual Care with Psycho-educational Manual |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Anxiety Score (HADS-A)
Change in the Hospital Anxiety and Depression Scale-Anxiety subscale (HADS-A) score from baseline to completion of radiotherapy. HADS-A consists of 7 items, each scored 0-3, with total score ranging from 0 to 21. Higher scores indicate more severe anxiety symptoms.
Measured: Baseline (within 1 week pre-radiotherapy) through 12 weeks post-radiotherapy
Secondary outcomes (3)
Change in Depression Score (HADS-D)
Change in the Hospital Anxiety and Depression Scale-Depression subscale (HADS-D) score from baseline to completion of radiotherapy. HADS-D consists of 7 items, each scored 0-3, with total score ranging from 0 to 21. Higher scores indicate more severe depressive symptoms.
Measured: Baseline (within 1 week pre-radiotherapy) through 12 weeks post-radiotherapy
Change in Combined HADS Total Score
Change in the combined Hospital Anxiety and Depression Scale total score (HADS-A + HADS-D, range 0-42) from baseline to completion of radiotherapy. Higher scores indicate greater overall psychological distress.
Measured: Baseline (within 1 week pre-radiotherapy) through 12 weeks post-radiotherapy
Prevalence of Severe Psychological Distress
Proportion of participants with a combined HADS total score ≥ 15 at radiotherapy completion.
Measured: Within 7 days post-radiotherapy
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Aug 2026
- Study start28 Aug 2026
- Primary completion1 Aug 2027 (estimated)
- Study completion1 Feb 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (14)Papers the sponsor has linked to this study.
- Other trials for Head and Neck Squamous Cell CarcinomaStudies of the same condition, open and under way.
- More trials run by West China HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Care provider, Outcomes assessor
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- West China Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Xingchen Peng, West China Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07766226
- Sponsor's protocol ID
- 2026-734
- Status last verified
- Aug 2026
- First submitted
- 7 Jul 2026
- Last updated
- 2 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Yang M, Zhang Z, Nice EC, Wang C, Zhang W, Huang C. Psychological intervention to treat distress: An emerging frontier in cancer prevention and therapy. Biochim Biophys Acta Rev Cancer. 2022 Jan;1877(1):188665. doi: 10.1016/j.bbcan.2021.188665. Epub 2021 Dec 9.
PubMed 34896258Zhang T, Ren Z, Wakefield CE, Hui BPH, Akechi T, Shi C, Du X, Chen W, Lai L, Zhao C, Li Y, Zhou Y. Are digital psychological interventions for psychological distress and quality of life in cancer patients effective? A systematic review and network meta-analysis. Clin Psychol Rev. 2025 Feb;115:102520. doi: 10.1016/j.cpr.2024.102520. Epub 2024 Nov 26.
PubMed 39615074Akdogan O, Uyar GC, Yesilbas E, Baskurt K, Malkoc NA, Ozdemir N, Yazici O, Oksuzoglu B, Uner A, Ozet A, Sutcuoglu O. Effect of a ChatGPT-based digital counseling intervention on anxiety and depression in patients with cancer: A prospective, randomized trial. Eur J Cancer. 2025 May 15;221:115408. doi: 10.1016/j.ejca.2025.115408. Epub 2025 Apr 3.
PubMed 40215593Kangas M, Milross C, Taylor A, Bryant RA. A pilot randomized controlled trial of a brief early intervention for reducing posttraumatic stress disorder, anxiety and depressive symptoms in newly diagnosed head and neck cancer patients. Psychooncology. 2013 Jul;22(7):1665-73. doi: 10.1002/pon.3208. Epub 2012 Oct 8.
PubMed 23042612van der Meulen IC, May AM, de Leeuw JR, Koole R, Oosterom M, Hordijk GJ, Ros WJ. Long-term effect of a nurse-led psychosocial intervention on health-related quality of life in patients with head and neck cancer: a randomised controlled trial. Br J Cancer. 2014 Feb 4;110(3):593-601. doi: 10.1038/bjc.2013.733. Epub 2013 Nov 26.
PubMed 24280999van der Meulen IC, May AM, Ros WJ, Oosterom M, Hordijk GJ, Koole R, de Leeuw JR. One-year effect of a nurse-led psychosocial intervention on depressive symptoms in patients with head and neck cancer: a randomized controlled trial. Oncologist. 2013;18(3):336-44. doi: 10.1634/theoncologist.2012-0299. Epub 2013 Feb 21.
PubMed 23429740De Leeuw JR, De Graeff A, Ros WJ, Hordijk GJ, Blijham GH, Winnubst JA. Negative and positive influences of social support on depression in patients with head and neck cancer: a prospective study. Psychooncology. 2000 Jan-Feb;9(1):20-8. doi: 10.1002/(sici)1099-1611(200001/02)9:13.0.co;2-y.
PubMed 10668056Panwar A, Lydiatt W, Osazuwa-Peters N. Genetic Depression Risk for Head and Neck Cancer Survivors-Fait Accompli? JAMA Otolaryngol Head Neck Surg. 2024 Jul 1;150(7):607-608. doi: 10.1001/jamaoto.2024.0377. No abstract available.
PubMed 38814662Fenech AL, Humphris GM, Laurenceau JP, Siegel SD, Rogers SN, Ozakinci G, Crawford JR, Pring M. Anxiety, depression, and fear of cancer recurrence in head and neck cancer. Health Psychol. 2024 Nov;43(11):803-812. doi: 10.1037/hea0001397. Epub 2024 Jul 25.
PubMed 39052377Barber B, Dergousoff J, Slater L, Harris J, O'Connell D, El-Hakim H, Biron VL, Mitchell N, Seikaly H. Depression and Survival in Patients With Head and Neck Cancer: A Systematic Review. JAMA Otolaryngol Head Neck Surg. 2016 Mar;142(3):284-8. doi: 10.1001/jamaoto.2015.3171.
PubMed 26796781Rao WW, Yang MJ, Cao BN, You YY, Zhang YY, Liu YY, Kou C, Yu Y, Cassidy RM, Yu Q, Zhang XY. Psychological distress in cancer patients in a large Chinese cross-sectional study. J Affect Disord. 2019 Feb 15;245:950-956. doi: 10.1016/j.jad.2018.11.089. Epub 2018 Nov 13.
PubMed 30699880Martinez MC, Finegersh A, Baik FM, Holsinger FC, Starmer HM, Orloff LA, Sunwoo JB, Sirjani D, Divi V, Chen MM. Comorbid Depression in Patients With Head and Neck Cancer Compared With Other Cancers. JAMA Otolaryngol Head Neck Surg. 2024 Dec 1;150(12):1097-1104. doi: 10.1001/jamaoto.2024.3233.
PubMed 39446380Bjordal K, Kaasa S, Mastekaasa A. Quality of life in patients treated for head and neck cancer: a follow-up study 7 to 11 years after radiotherapy. Int J Radiat Oncol Biol Phys. 1994 Mar 1;28(4):847-56. doi: 10.1016/0360-3016(94)90104-x.
PubMed 8138437Chow LQM. Head and Neck Cancer. N Engl J Med. 2020 Jan 2;382(1):60-72. doi: 10.1056/NEJMra1715715. No abstract available.
PubMed 31893516
Study at a glance
From the registry record, last updated by the sponsor on 2 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Randomized Controlled Trial of Network Platform Sharing Intervention for Psychological Outcomes in Patients With Head and Neck Squamous Cell Carcinoma Undergoing Radiotherapy
- ClinicalTrials.gov ID
- NCT07766226
- Acronym / sponsor ID
- 2026-734
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- West China HospitalUniversity, hospital or other
- Study start
- 28 Aug 2026 (actual)
- Primary completion
- 1 Aug 2027 (estimated)
- Study completion
- 1 Feb 2028 (estimated)
- First posted
- 14 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Head and neck cancer patients often experience significant anxiety and depression during radiation therapy, which can affect their quality of life and treatment adherence. However, traditional psychological support is limited by resource constraints and accessibility. This study aims to evaluate whether a mobile application based on social sharing and peer interaction can improve psychological distress in patients with head and neck squamous cell carcinoma (HNSCC) undergoing radiotherapy.
This is a prospective, randomized, parallel-group, open-label trial. A total of 120 participants will be randomly assigned in a 1:1 ratio to either the immediate intervention group or a waitlist control group. Participants in the intervention group will use a dedicated app featuring daily sharing, peer interaction (anonymous comments, likes, private messaging), psychoeducational resources, and reminders. The control group will receive a printed psychoeducational booklet during the initial phase and will gain access to the app after the primary endpoint assessment.
The primary outcome is the change in anxiety score (HADS-A) from baseline to completion of radiotherapy. Secondary outcomes include depression scores (HADS-D), radiotherapy interruption rate, app engagement, and severe psychological distress prevalence. Exploratory outcomes include quality of life (EORTC QLQ-C30, H\&N35), readmission rate, adverse event severity (CTCAE v5.0), and biological markers (e.g., cortisol, IL-6, CRP).
The study is expected to run from April 2026 to August 2027. Findings may inform scalable digital psychosocial interventions for cancer patients.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (care provider, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Online Sharing Group | Experimental | Other: Social Sharing-Based Mobile ApplicationParticipants receive immediate access to the social sharing-based mobile app intervention. The active intervention phase begins at radiotherapy initiation and lasts for 8 weeks, through 4 weeks post-radiotherapy, during which participants are encouraged to post at least 2 shares and complete at least 3 interactions per week. App access remains open thereafter for voluntary use through 12 weeks post-radiotherapy. |
| Control Group | Other | Other: Usual Care with Psycho-educational ManualParticipants receive a printed psychoeducational booklet during the initial phase and will gain access to the same app intervention after the primary endpoint assessment (radiotherapy completion). |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Age 18 - 75 years, male or female
- Life expectancy ≥ 6 months
- Histopathologically confirmed head and neck squamous cell carcinoma (including nasopharyngeal carcinoma) without distant metastasis
- Planned to receive curative radiotherapy or postoperative adjuvant radiotherapy
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
Key exclusion criteria (5 listed)
- Other malignancies (except treated basal cell skin cancer or cervical CIS)
- Prior head and neck radiotherapy
- History of psychiatric disorder or psychotropic medication use
- Absolute contraindication to head and neck radiotherapy
- Uncontrolled systemic disease (poorly controlled DM, NYHA III-IV HF, interstitial lung disease)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Social Sharing-Based Mobile ApplicationMobile app with five modules: daily sharing, anonymous peer interaction, psychoeducational resources, task reminders, and professional support. Participants post ≥2 shares and interact ≥3 times weekly for 8 weeks. Content moderated by research assistants. | Other | Online Sharing Group |
| Usual Care with Psycho-educational ManualParticipants receive standard radiotherapy care and a printed psychological adjustment manual, without access to the social sharing APP during the initial intervention phase. | Other | Control Group |
Primary outcome
Change in Anxiety Score (HADS-A)
Time frame: Baseline (within 1 week pre-radiotherapy) through 12 weeks post-radiotherapy
Change in the Hospital Anxiety and Depression Scale-Anxiety subscale (HADS-A) score from baseline to completion of radiotherapy. HADS-A consists of 7 items, each scored 0-3, with total score ranging from 0 to 21. Higher scores indicate more severe anxiety symptoms.
3 secondary outcomes
Change in Depression Score (HADS-D)
Time frame: Baseline (within 1 week pre-radiotherapy) through 12 weeks post-radiotherapy
Change in Combined HADS Total Score
Time frame: Baseline (within 1 week pre-radiotherapy) through 12 weeks post-radiotherapy
Prevalence of Severe Psychological Distress
Time frame: Within 7 days post-radiotherapy
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Sep 2026.
- Background: PubMed 34896258Yang M, Zhang Z, Nice EC, Wang C, Zhang W, Huang C. Psychological intervention to treat distress: An emerging frontier in cancer prevention and therapy. Biochim Biophys Acta Rev Cancer. 2022 Jan;1877(1):188665. doi: 10.1016/j.bbcan.2021.188665. Epub 2021 Dec 9.
- Background: PubMed 39615074Zhang T, Ren Z, Wakefield CE, Hui BPH, Akechi T, Shi C, Du X, Chen W, Lai L, Zhao C, Li Y, Zhou Y. Are digital psychological interventions for psychological distress and quality of life in cancer patients effective? A systematic review and network meta-analysis. Clin Psychol Rev. 2025 Feb;115:102520. doi: 10.1016/j.cpr.2024.102520. Epub 2024 Nov 26.
- Background: PubMed 40215593Akdogan O, Uyar GC, Yesilbas E, Baskurt K, Malkoc NA, Ozdemir N, Yazici O, Oksuzoglu B, Uner A, Ozet A, Sutcuoglu O. Effect of a ChatGPT-based digital counseling intervention on anxiety and depression in patients with cancer: A prospective, randomized trial. Eur J Cancer. 2025 May 15;221:115408. doi: 10.1016/j.ejca.2025.115408. Epub 2025 Apr 3.
- Background: PubMed 23042612Kangas M, Milross C, Taylor A, Bryant RA. A pilot randomized controlled trial of a brief early intervention for reducing posttraumatic stress disorder, anxiety and depressive symptoms in newly diagnosed head and neck cancer patients. Psychooncology. 2013 Jul;22(7):1665-73. doi: 10.1002/pon.3208. Epub 2012 Oct 8.
- Background: PubMed 24280999van der Meulen IC, May AM, de Leeuw JR, Koole R, Oosterom M, Hordijk GJ, Ros WJ. Long-term effect of a nurse-led psychosocial intervention on health-related quality of life in patients with head and neck cancer: a randomised controlled trial. Br J Cancer. 2014 Feb 4;110(3):593-601. doi: 10.1038/bjc.2013.733. Epub 2013 Nov 26.
- Background: PubMed 23429740van der Meulen IC, May AM, Ros WJ, Oosterom M, Hordijk GJ, Koole R, de Leeuw JR. One-year effect of a nurse-led psychosocial intervention on depressive symptoms in patients with head and neck cancer: a randomized controlled trial. Oncologist. 2013;18(3):336-44. doi: 10.1634/theoncologist.2012-0299. Epub 2013 Feb 21.
- Background: PubMed 10668056De Leeuw JR, De Graeff A, Ros WJ, Hordijk GJ, Blijham GH, Winnubst JA. Negative and positive influences of social support on depression in patients with head and neck cancer: a prospective study. Psychooncology. 2000 Jan-Feb;9(1):20-8. doi: 10.1002/(sici)1099-1611(200001/02)9:13.0.co;2-y.
- Background: PubMed 38814662Panwar A, Lydiatt W, Osazuwa-Peters N. Genetic Depression Risk for Head and Neck Cancer Survivors-Fait Accompli? JAMA Otolaryngol Head Neck Surg. 2024 Jul 1;150(7):607-608. doi: 10.1001/jamaoto.2024.0377. No abstract available.
- Background: PubMed 39052377Fenech AL, Humphris GM, Laurenceau JP, Siegel SD, Rogers SN, Ozakinci G, Crawford JR, Pring M. Anxiety, depression, and fear of cancer recurrence in head and neck cancer. Health Psychol. 2024 Nov;43(11):803-812. doi: 10.1037/hea0001397. Epub 2024 Jul 25.
- Background: PubMed 26796781Barber B, Dergousoff J, Slater L, Harris J, O'Connell D, El-Hakim H, Biron VL, Mitchell N, Seikaly H. Depression and Survival in Patients With Head and Neck Cancer: A Systematic Review. JAMA Otolaryngol Head Neck Surg. 2016 Mar;142(3):284-8. doi: 10.1001/jamaoto.2015.3171.
- Background: PubMed 30699880Rao WW, Yang MJ, Cao BN, You YY, Zhang YY, Liu YY, Kou C, Yu Y, Cassidy RM, Yu Q, Zhang XY. Psychological distress in cancer patients in a large Chinese cross-sectional study. J Affect Disord. 2019 Feb 15;245:950-956. doi: 10.1016/j.jad.2018.11.089. Epub 2018 Nov 13.
- Background: PubMed 39446380Martinez MC, Finegersh A, Baik FM, Holsinger FC, Starmer HM, Orloff LA, Sunwoo JB, Sirjani D, Divi V, Chen MM. Comorbid Depression in Patients With Head and Neck Cancer Compared With Other Cancers. JAMA Otolaryngol Head Neck Surg. 2024 Dec 1;150(12):1097-1104. doi: 10.1001/jamaoto.2024.3233.
- Individual participant dataSharing planned: No
Related trials for Head and Neck Squamous Cell Carcinoma
RecruitingPhase 1
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Advanced/Metastatic Solid Tumors, Bladder Cancer
Not yet recruitingPhase 1/2
Intravenously Administered PROMITIL Combined With Radiotherapy in Patients With Cisplatin-Ineligible Head and Neck Cancer Patients
Head & Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Not yet recruitingObservational study
Standardized Management of Esophageal Fistula in Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma (ESCC), Esophageal Fistula
RecruitingPhase 2
Effectiveness of Phenotype-based Pain Management Guidelines for Head and Neck Cancer Related Pain: a Pilot Study
Cancer Pain, Orofacial Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Social Sharing-Based Mobile Application in people with Head and Neck Squamous Cell Carcinoma, run by West China Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Xingchen Peng (+86 18980606753, pxx2014@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Anxiety Score (HADS-A) (time frame: Baseline (within 1 week pre-radiotherapy) through 12 weeks post-radiotherapy). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07766226, which also lists 14 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Sep 2026.